Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results
Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2021 fourth quarter and year-end earnings on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Participants can join via phone or listen to a webcast on the Investor Relations page of the company’s website. Telephonic replays will be available for a week post-call. Prestige markets various consumer healthcare products across North America and internationally, with well-known brands like Monistat®, Summer’s Eve®, and Dramamine®.
- None.
- None.
TARRYTOWN, N.Y., April 08, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 fourth quarter and year-end earnings release on Thursday, May 6, 2021 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 5996287. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.
Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 5996287.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
FAQ
When will Prestige Consumer Healthcare announce its Q4 and year-end earnings for fiscal 2021?
What time is the conference call for Prestige's earnings release?
How can I participate in the Prestige Consumer Healthcare earnings call?
Will there be a replay of the conference call for Prestige's earnings?